摘要
目的:探讨联合应用丁苯酞治疗对非致残性缺血性脑血管病患者ABCD2评分、相关分子标志物等的影响,并评价其临床治疗效果。方法:选取2021年2月至2023年2月于该院住院治疗的非致残性缺血性脑血管病患者100例,通过乱数表工具以随机抽样法分为观察组(n=50)和对照组(n=50)。对照组患者给予常规脑血管病治疗方案,观察组患者在对照组的基础上联合丁苯酞治疗,所有患者均连续治疗1个月。比较两组患者治疗前后的ABCD2评分、美国国立卫生院卒中神经功能缺损评分量表(NIHSS)评分和日常生活活动量表(ADL)评分变化,C反应蛋白(CRP)、同型半胱氨酸(Hcy)、S100A1蛋白、白细胞介素6(IL-6)及超氧化物歧化酶(SOD)水平变化,评价两组患者的临床疗效及安全性。结果:治疗后,观察组患者的ABCD2评分、NIHSS评分明显低于对照组,ADL评分高于对照组,差异均有统计学意义(P<0.05);治疗后,观察组患者的CRP、Hcy、S100A1蛋白和IL-6水平显著低于对照组,SOD水平显著高于对照组,差异均有统计学意义(P<0.05)。观察组患者的总有效率[94.00%(47/50)vs. 84.00%(42/50)]、不良事件发生率[12.00%(6/50)vs. 10.00%(5/50)]均高于对照组,但差异均无统计学意义(P>0.05)。结论:在常规脑血管病治疗方案基础上联合应用丁苯酞,可有效降低非致残性缺血性脑血管病患者的脑卒中风险,减轻神经功能损伤,有利于炎症、氧化应激水平降低,具有一定的临床应用价值。
OBJECTIVE:To probe into the effects of combined application of butylphthalide on ABCD2 score and related molecular markers in patients with non-disabling ischemic cerebrovascular disease,and to evaluate its clinical therapeutic effect.METHODS:A total of 100 patients with non-disabling ischemic cerebrovascular disease hospitalized in the hospital from Feb.2021 to Feb.2023 were selected to be divided into the observation group(n=50)and control group(n=50)by random sampling method through random number table tool.The control group was given conventional cerebrovascular disease treatment regimen,while the observation group received butylphthalide on the basis of the control group,all patients were treated continuously for 1 month.Changes of ABCD2 scores,National Institutes of Health Stroke Neurological Impairment Scale(NIHSS)scores and Activity of Daily Living(ADL)scores,C-reactive protein(CRP),homocysteine(Hcy),S100A1 protein,interleukin 6(IL-6)and superoxide dismutase(SOD)levels were compared between two groups before and after treatment,the clinical efficacy and safety of two groups were evaluated.RESULTS:After treatment,the ABCD2 score and NIHSS score were lower,the ADL score was higher in the observation group than those in the control group,with statistically significant differences(P<0.05).After treatment,the CRP,Hcy,S100A1 protein and IL-6 levels were significantly lower,the SOD level was significantly higher in the observation group than those in the control group,with statistically significant differences(P<0.05).The total effective rate[94.00%(47/50)vs.84.00%(42/50)]and incidence of adverse event[12.00%(6/50)vs.10.00%(5/50)]of the observation group were higher than those of the control group,the differences were not statistically significant(P>0.05).CONCLUSIONS:Butylphthalide treatment based on conventional cerebrovascular disease regimen can effectively reduce the risk of stroke in patients with non-disabling ischemic cerebrovascular disease,relief neurological function damage,contribute to the reduction of inflammation and oxidative stress levels,which has certain clinical application value.
作者
崔浩
卢慧敏
刘娜
CUI Hao;LU Huimin;LIU Na(Dept.of Neurology,the Second Hospital of Shijiazhuang,Shijiazhuang 050000,China)
出处
《中国医院用药评价与分析》
2024年第8期940-943,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
2019年度河北省医学科学研究重点课题计划(No.20191413)。
